{"log_id": 695949313499126284, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.000391, "average": 0.993889, "min": 0.889526}, "location": {"width": 631, "top": 153, "height": 28, "left": 196}, "words": "儿童用药:尚未对小于18岁的患者进行非布司他的药代动力学研究"}, {"probability": {"variance": 9.2e-05, "average": 0.99561, "min": 0.946917}, "location": {"width": 802, "top": 189, "height": 28, "left": 196}, "words": "老年人用药:与年轻受试者相比(18~40岁),老年受试者(65岁及以上)多次口服"}, {"probability": {"variance": 0.000955, "average": 0.989019, "min": 0.83146}, "location": {"width": 845, "top": 225, "height": 31, "left": 155}, "words": "非布司他后,非布司他及其代谢物的Cmx和AUC相似。血清尿酸浓度下降率在年老与年轻"}, {"probability": {"variance": 0.000153, "average": 0.995629, "min": 0.942628}, "location": {"width": 451, "top": 262, "height": 29, "left": 155}, "words": "的受试者中也基本一致。老年患者无需调整剂量"}, {"probability": {"variance": 0.000908, "average": 0.98962, "min": 0.850635}, "location": {"width": 803, "top": 300, "height": 29, "left": 196}, "words": "肾功能不全者:在轻度(肌酐清除率50~80m/min)、中度(肌酐清除率30~49"}, {"probability": {"variance": 0.004889, "average": 0.974432, "min": 0.688009}, "location": {"width": 838, "top": 336, "height": 28, "left": 156}, "words": "m/min)或重度(肌酐清除率10~29ml/min)的肾功能不全的健康受试者中,多次服用80mg"}, {"probability": {"variance": 0.001047, "average": 0.98619, "min": 0.85857}, "location": {"width": 838, "top": 372, "height": 29, "left": 156}, "words": "的非布司他,与肾功能正常受试者(肌酐清除率大于80m/min)相比,Cmax无变化,AUC"}, {"probability": {"variance": 0.002712, "average": 0.984592, "min": 0.680173}, "location": {"width": 843, "top": 408, "height": 30, "left": 156}, "words": "与半衰期增加,但肾功能不全的3组中,结果相似。肾功能不全者平均非布司他AUC值是"}, {"probability": {"variance": 0.000467, "average": 0.992629, "min": 0.863447}, "location": {"width": 846, "top": 446, "height": 30, "left": 153}, "words": "正常者的1.8倍,3种活性代谢物的平均Cmax和AUC分别增加到2倍和4倍。但是,肾功"}, {"probability": {"variance": 0.00048, "average": 0.992539, "min": 0.859474}, "location": {"width": 803, "top": 484, "height": 29, "left": 155}, "words": "能不全者的血清尿酸下降率与正常者类似(正常者是58%,重度肾功能不全者是55%)"}, {"probability": {"variance": 2.2e-05, "average": 0.997177, "min": 0.973413}, "location": {"width": 785, "top": 520, "height": 30, "left": 197}, "words": "轻度至中度肾功能不全者的药物剂量无需调整。非布司他的推荐起始剂量为40mg"}, {"probability": {"variance": 0.013817, "average": 0.96126, "min": 0.352206}, "location": {"width": 843, "top": 559, "height": 28, "left": 155}, "words": "每日一次。服用2周后血清尿酸未达到6mg/d以下者,推荐服用80mg。重度肾功能不全"}, {"probability": {"variance": 4e-06, "average": 0.998441, "min": 0.99217}, "location": {"width": 259, "top": 597, "height": 27, "left": 154}, "words": "者数据不充分,请谨慎使用"}, {"probability": {"variance": 0.007847, "average": 0.981163, "min": 0.529537}, "location": {"width": 579, "top": 633, "height": 26, "left": 195}, "words": "非布司他在肾功能损害末期需要进行透析的患者中未进行研究"}, {"probability": {"variance": 0.009329, "average": 0.971719, "min": 0.499217}, "location": {"width": 804, "top": 667, "height": 30, "left": 195}, "words": "肝功能不全:轻度( Child- Pugh A级)或者中度( child-pugh B级)肝功能不全者,相"}, {"probability": {"variance": 0.001057, "average": 0.985561, "min": 0.822736}, "location": {"width": 845, "top": 705, "height": 28, "left": 154}, "words": "对于正常肝功能者,多次服用80mg的非布司他,Cmax与AUC24(总量与游离态)平均增加"}, {"probability": {"variance": 0.000162, "average": 0.994216, "min": 0.936555}, "location": {"width": 844, "top": 740, "height": 29, "left": 154}, "words": "了20%~30%在不同的组别中,血清尿酸浓度下降率类似(健康组62%,轻度肝功能不全"}, {"probability": {"variance": 0.002061, "average": 0.986334, "min": 0.71416}, "location": {"width": 847, "top": 778, "height": 29, "left": 152}, "words": "组49%,中度肝功能不全组48%)。轻度与中度肝功能不全者的药物剂量无需调整。尚未"}, {"probability": {"variance": 0.00116, "average": 0.989589, "min": 0.819907}, "location": {"width": 680, "top": 814, "height": 32, "left": 153}, "words": "对重度肝功能损害者( child-pugh C级)进行研究,此类患者应谨慎使用"}, {"probability": {"variance": 0.00164, "average": 0.984047, "min": 0.77328}, "location": {"width": 803, "top": 851, "height": 30, "left": 196}, "words": "性别:多次口服非布司他,女性比男性的非布司他Cmax和AUC24分别高出30%和"}, {"probability": {"variance": 0.008856, "average": 0.977869, "min": 0.387618}, "location": {"width": 844, "top": 890, "height": 28, "left": 155}, "words": "14%然而进行体重矫正后,Cmax与AUC在两性别中相似。此外,性别间的血清尿酸浓度"}, {"probability": {"variance": 2.1e-05, "average": 0.99749, "min": 0.981566}, "location": {"width": 449, "top": 927, "height": 26, "left": 156}, "words": "下降率也相似。无需根据性别进行药物剂量调整"}, {"probability": {"variance": 3e-05, "average": 0.996606, "min": 0.979794}, "location": {"width": 473, "top": 962, "height": 27, "left": 194}, "words": "种族:尚未对不同种族进行特殊药代动力学的研究"}, {"probability": {"variance": 0, "average": 0.999675, "min": 0.999311}, "location": {"width": 130, "top": 1001, "height": 25, "left": 197}, "words": "药物相互作用"}, {"probability": {"variance": 0.002256, "average": 0.981766, "min": 0.827265}, "location": {"width": 262, "top": 1038, "height": 27, "left": 194}, "words": "非布司他对其它药物的影响"}, {"probability": {"variance": 0.000864, "average": 0.99221, "min": 0.820365}, "location": {"width": 802, "top": 1074, "height": 28, "left": 197}, "words": "黄嘌呤氧化酶底物类药物硫唑嘌呤、巯嘌呤和茶碱:非布司他是一个黄嘌呤氧化酶抑"}, {"probability": {"variance": 0.000139, "average": 0.995566, "min": 0.940747}, "location": {"width": 826, "top": 1111, "height": 30, "left": 153}, "words": "制剂。一项以健康受试者为试验对象、旨在评估本品对茶碱药代动力学影响的试验表明"}, {"probability": {"variance": 0.00633, "average": 0.985669, "min": 0.488949}, "location": {"width": 825, "top": 1148, "height": 30, "left": 154}, "words": "本品与茶碱同时服用将导致尿中茶碱的主要代谢物之一1-甲基黄嘌呤的含量增大400倍"}, {"probability": {"variance": 0.000578, "average": 0.993255, "min": 0.849047}, "location": {"width": 845, "top": 1185, "height": 30, "left": 154}, "words": "由于人体长期暴露于1-甲基黄嘌呤的安全性尚不明确,故非布司他与茶碱同时给药时应谨"}, {"probability": {"variance": 0, "average": 0.995826, "min": 0.995826}, "location": {"width": 28, "top": 1226, "height": 27, "left": 154}, "words": "慎"}, {"probability": {"variance": 0.000311, "average": 0.990701, "min": 0.900929}, "location": {"width": 783, "top": 1258, "height": 31, "left": 195}, "words": "本品与通过黄嘌呤氧化酶代谢的药物(如硫唑嘌呤和巯嘌呤)的相互作用未进行研究"}, {"probability": {"variance": 0.00021, "average": 0.99483, "min": 0.914719}, "location": {"width": 845, "top": 1296, "height": 29, "left": 154}, "words": "本品对黄嘌呤氧化酶的抑制可能会导致这些药物血浆浓度升高,进而产生毒性。本品禁用"}, {"probability": {"variance": 0.001303, "average": 0.985465, "min": 0.802298}, "location": {"width": 619, "top": 1332, "height": 34, "left": 156}, "words": "于正在接受硫唑嘌呤、巯嘌呤治疗的患者[见禁忌和药物相互作用]。"}, {"probability": {"variance": 0.00017, "average": 0.993658, "min": 0.940938}, "location": {"width": 783, "top": 1370, "height": 33, "left": 195}, "words": "硫唑嘌呤和巯嘌呤通过三个主要代谢途径进行代谢,其中一个由黄嘌呤氧化酶介导"}, {"probability": {"variance": 4.5e-05, "average": 0.994347, "min": 0.976904}, "location": {"width": 844, "top": 1409, "height": 32, "left": 155}, "words": "虽然未进行本品与硫唑嘌呤和巯嘌呤药物相互作用的研究,但是别嘌呤醇(一个黄嘌呤氧化"}, {"probability": {"variance": 0.002379, "average": 0.987185, "min": 0.686795}, "location": {"width": 840, "top": 1447, "height": 32, "left": 160}, "words": "酶抑制剂)与硫唑嘌呤或巯嘌呤同时给药已发现这些药物血药浓度有显著升高。因为本品是"}, {"probability": {"variance": 0.000443, "average": 0.992089, "min": 0.882231}, "location": {"width": 839, "top": 1486, "height": 29, "left": 162}, "words": "一个黄嘌呤氧化酶抑制剂,所以它可以抑制硫唑嘌呤和巯嘌呤由黄嘌呤氧化酶介导的代"}, {"probability": {"variance": 0.000168, "average": 0.995076, "min": 0.93098}, "location": {"width": 579, "top": 1522, "height": 32, "left": 155}, "words": "谢,导致硫唑嘌呤或巯嘌呤血药浓度升高,可能导致严重毒性"}, {"probability": {"variance": 0.000172, "average": 0.993597, "min": 0.921337}, "location": {"width": 784, "top": 1560, "height": 28, "left": 195}, "words": "P450底物药物:体外研究表明非布司他临床相关浓度时不会抑制P450酶CYP1A2"}], "language": 3}